Humacyte Inc (HUMAW NASDAQ) stock market data APIs
$0.1219
0(0%)
as of December 4, 2025
Try our APIs with
free plan!
Humacyte Inc Financial Data Overview
Price chart is built with
Anychart
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Prev. Close
0.1219
Open
0.1223
High
0.1232
Low
0.1217
52 wk Range
0.1001-2.375
Market Cap
0
Revenue
1 571 K
EPS
-0.7181
Beta
1.897
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Humacyte Inc data using free add-ons & libraries
Get Humacyte Inc Fundamental Data
Humacyte Inc Fundamental data includes:
- Net Revenue: 1 571 K
- EBITDA: -97 324 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Humacyte Inc News
New
Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise
Earnings Call Insights: Humacyte, Inc. (HUMA) Q3 2025 MANAGEMENT VIEW * Laura Niklason, Founder, President, CEO & Director, highlighted significant progress in the commercial launch of Symvess, re...
Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway
Earnings Call Insights: Humacyte, Inc. (HUMA) Q2 2025 MANAGEMENT VIEW * CEO Laura E. Niklason reported significant expansion in commercial access for Symvess, following its FDA approval for extrem...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
